SummaryThe combination of various cytostatic products, each with a different mode of action, in the treatment of inoperable bronchia] carcinoma, results in a high percentage of radiological and objective clinical improvements, and seems to influence the survival time favourably. If the patients are controlled carefully side effects remain within reasonable limits. Justification of the selected combination and possible further improvements are discussed.